HBK Sorce Advisory’s Agios Pharmaceuticals AGIO Stock Holding History

HBK Sorce Advisory’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-73,798	Closed	-$331K	–	595
2022 Q4	$331K	Buy	73,798 +17,899	+32%	+$504K	0.01%	524
2022 Q3	$169K	Buy	+55,899	New	+$1.5M	0.01%	469
2021 Q4	–	Sell	-5,899	Closed	-$272K	–	596
2021 Q3	$272K	Hold	5,899	–	–	0.02%	470
2021 Q2	$325K	Hold	5,899	–	–	0.02%	428
2021 Q1	$305K	Hold	5,899	–	–	0.02%	400
2020 Q4	$256K	Hold	5,899	–	–	0.02%	416
2020 Q3	$206K	Buy	+5,899	New	+$259K	0.01%	419

Other funds holding AGIO

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

HBK Sorce Advisory's AGIO Position: Q1 2023 in Review

HBK Sorce Advisory sold out of Agios Pharmaceuticals (AGIO) in Q1 2023, closing a stake of 73,798 shares — an estimated $331K sold.

HBK Sorce Advisory first reported a position in AGIO in Q3 2020 and held it in 7 quarters. The position peaked at $331K in Q4 2022. 164 funds tracked by Wall St. Rank hold AGIO as of Q1 2023.

HBK Sorce Advisory reported no remaining Agios Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
HBK Sorce Advisory sold 73,798 Agios Pharmaceuticals shares in Q1 2023, an estimated $331K.
HBK Sorce Advisory first reported a position in Agios Pharmaceuticals in Q3 2020 and held it in 7 quarters.
HBK Sorce Advisory's Agios Pharmaceuticals position peaked at $331K in Q4 2022.
164 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2023.

Based on HBK Sorce Advisory's 13F filing for Q1 2023, filed 15 May 2023.